Low density lipoprotein (LDL) apheresis is utilized in clinical practice with patients suffering from lipid disorders with a high and very high cardiovascular risk. One treatment allows to reduce the concentration of LDL by 55 – 80%. These treatments are recommended primarily for patients with a familial homozygous hypercholesterolemia, for whom treatments should be commenced as early as at the age of 5-8 years old. Therapy is also used for patients with a heterozygous form of hypercholesterolemia if, despite maximum doses of statins, further progress of clinically symptomatic atherosclerosis is observed. Apheresis is recommended when, despite a diet and maximum tolerable pharmacotherapy, the concentration of LDL is ≥ 300 mg/dl (7,7 mmol/l) or ≥ 200 mg/dl (5,2 mmol/l) throughout 6 months for patients with documented coronary heart disease. In recent years an indication to perform apheresis is also an isolated increase of lipoprotein (a), with values >60 mg/dl. The apheresis treatment lasts 2-3 hours and must be repeated every 1-2 weeks for the rest of the patient’s life, it is safe and not associated with dangerous complications. Below we present the current state of knowledge regarding LA with a description of own experience.
Select your language of interest to view the total content in your interested language
Annals of Medical and Health Sciences Research received 15898 citations as per google scholar report